OTLK vs CBIO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
OTLK Captures Institutional Edge (2โ2 Pillars ยท 5โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Outlook Therapeutics, Inc. Common Stock (OTLK) driven by superior Valuation, Growth & Margin while CBIO counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, OTLK trades at 2.9x Forward P/E with 4781.8% operating margin (-99.4% YoY revenue) versus CBIO at N/M Forward P/E and -1432.6% operating margin (+0.0% YoY). In options structure, OTLK sits in BREAKDOWN (55th %ile IV; Dealer Gamma Walls on Pro) against CBIO sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | OTLK Revenue | CBIO Revenue | OTLK Op. Margin | CBIO Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2017 | $0M | N/A | -941.4% | N/A | OTLK |
| FY2018 | $0M | N/A | -960.1% | N/A | OTLK |
| FY2019 | $10M | N/A | -445.6% | N/A | OTLK |
| FY2020 | N/A | $10M | N/A | -506.8% | CBIO |
| FY2021 | N/A | $0M | N/A | -5470.7% | CBIO |
| FY2022 | N/A | $0M | N/A | -63204.4% | CBIO |
| FY2023 | N/A | $0M | N/A | -392752.9% | CBIO |
| FY2025 | $0M | $10M | -4744.3% | -1407.5% | CBIO |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | OTLK | CBIO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $107.1M | $533.8M | Larger Scale | CBIO |
| Trailing P/E Ratio Valuation | 2.9x | N/M | Lower Multiple | OTLK |
| Forward P/E Ratio Valuation | 2.9x | N/M | Lower Multiple | OTLK |
| Revenue Growth (YoY) Growth | -99.4% | +0.0% | Higher Growth | CBIO |
| Operating Margin (TTM) Profitability | 4781.8% | -1432.6% | Higher Margin | OTLK |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -3.6% | -160.8% | Higher ROE | OTLK |
| 52-Week Range Position Momentum | 10% ($0โ$3) | 23% ($9โ$27) | Stronger Trend | CBIO |
| Beta / 30D Volatility Risk Regime | 1.47ฮฒ ยท 79% Vol | 1.41ฮฒ ยท 62% Vol | Lower Realized Risk | CBIO |
| Unified Institutional Score Composite Signal | 48.6 / 100 (HOLD) | 37.4 / 100 (SELL) | Higher Composite | OTLK |